Cargando…

Drug repurposing and prediction of multiple interaction types via graph embedding

BACKGROUND: Finding drugs that can interact with a specific target to induce a desired therapeutic outcome is key deliverable in drug discovery for targeted treatment. Therefore, both identifying new drug–target links, as well as delineating the type of drug interaction, are important in drug repurp...

Descripción completa

Detalles Bibliográficos
Autores principales: Amiri Souri, E., Chenoweth, A., Karagiannis, S. N., Tsoka, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190044/
https://www.ncbi.nlm.nih.gov/pubmed/37193964
http://dx.doi.org/10.1186/s12859-023-05317-w
_version_ 1785043206540361728
author Amiri Souri, E.
Chenoweth, A.
Karagiannis, S. N.
Tsoka, S.
author_facet Amiri Souri, E.
Chenoweth, A.
Karagiannis, S. N.
Tsoka, S.
author_sort Amiri Souri, E.
collection PubMed
description BACKGROUND: Finding drugs that can interact with a specific target to induce a desired therapeutic outcome is key deliverable in drug discovery for targeted treatment. Therefore, both identifying new drug–target links, as well as delineating the type of drug interaction, are important in drug repurposing studies. RESULTS: A computational drug repurposing approach was proposed to predict novel drug–target interactions (DTIs), as well as to predict the type of interaction induced. The methodology is based on mining a heterogeneous graph that integrates drug–drug and protein–protein similarity networks, together with verified drug-disease and protein-disease associations. In order to extract appropriate features, the three-layer heterogeneous graph was mapped to low dimensional vectors using node embedding principles. The DTI prediction problem was formulated as a multi-label, multi-class classification task, aiming to determine drug modes of action. DTIs were defined by concatenating pairs of drug and target vectors extracted from graph embedding, which were used as input to classification via gradient boosted trees, where a model is trained to predict the type of interaction. After validating the prediction ability of DT2Vec+, a comprehensive analysis of all unknown DTIs was conducted to predict the degree and type of interaction. Finally, the model was applied to propose potential approved drugs to target cancer-specific biomarkers. CONCLUSION: DT2Vec+ showed promising results in predicting type of DTI, which was achieved via integrating and mapping triplet drug–target–disease association graphs into low-dimensional dense vectors. To our knowledge, this is the first approach that addresses prediction between drugs and targets across six interaction types. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-023-05317-w.
format Online
Article
Text
id pubmed-10190044
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101900442023-05-18 Drug repurposing and prediction of multiple interaction types via graph embedding Amiri Souri, E. Chenoweth, A. Karagiannis, S. N. Tsoka, S. BMC Bioinformatics Research BACKGROUND: Finding drugs that can interact with a specific target to induce a desired therapeutic outcome is key deliverable in drug discovery for targeted treatment. Therefore, both identifying new drug–target links, as well as delineating the type of drug interaction, are important in drug repurposing studies. RESULTS: A computational drug repurposing approach was proposed to predict novel drug–target interactions (DTIs), as well as to predict the type of interaction induced. The methodology is based on mining a heterogeneous graph that integrates drug–drug and protein–protein similarity networks, together with verified drug-disease and protein-disease associations. In order to extract appropriate features, the three-layer heterogeneous graph was mapped to low dimensional vectors using node embedding principles. The DTI prediction problem was formulated as a multi-label, multi-class classification task, aiming to determine drug modes of action. DTIs were defined by concatenating pairs of drug and target vectors extracted from graph embedding, which were used as input to classification via gradient boosted trees, where a model is trained to predict the type of interaction. After validating the prediction ability of DT2Vec+, a comprehensive analysis of all unknown DTIs was conducted to predict the degree and type of interaction. Finally, the model was applied to propose potential approved drugs to target cancer-specific biomarkers. CONCLUSION: DT2Vec+ showed promising results in predicting type of DTI, which was achieved via integrating and mapping triplet drug–target–disease association graphs into low-dimensional dense vectors. To our knowledge, this is the first approach that addresses prediction between drugs and targets across six interaction types. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-023-05317-w. BioMed Central 2023-05-17 /pmc/articles/PMC10190044/ /pubmed/37193964 http://dx.doi.org/10.1186/s12859-023-05317-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Amiri Souri, E.
Chenoweth, A.
Karagiannis, S. N.
Tsoka, S.
Drug repurposing and prediction of multiple interaction types via graph embedding
title Drug repurposing and prediction of multiple interaction types via graph embedding
title_full Drug repurposing and prediction of multiple interaction types via graph embedding
title_fullStr Drug repurposing and prediction of multiple interaction types via graph embedding
title_full_unstemmed Drug repurposing and prediction of multiple interaction types via graph embedding
title_short Drug repurposing and prediction of multiple interaction types via graph embedding
title_sort drug repurposing and prediction of multiple interaction types via graph embedding
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190044/
https://www.ncbi.nlm.nih.gov/pubmed/37193964
http://dx.doi.org/10.1186/s12859-023-05317-w
work_keys_str_mv AT amirisourie drugrepurposingandpredictionofmultipleinteractiontypesviagraphembedding
AT chenowetha drugrepurposingandpredictionofmultipleinteractiontypesviagraphembedding
AT karagiannissn drugrepurposingandpredictionofmultipleinteractiontypesviagraphembedding
AT tsokas drugrepurposingandpredictionofmultipleinteractiontypesviagraphembedding